Effects of a New Antithrombotic Drug GRS, a Soluble Guanylate Cyclase Stimulator, on Endothelial Dysfunction in Rats with Myocardial Infarction

• DOI: 10.1007/s10517-022-05461-y
• Publication Date: 2022-05-02T18:02:42Z
• Authors: V. V. Bykov; V. I. Smol’yakova; G. A. Chernysheva; O. I. Aliev; A. M. Anishchenko; A. V. Sidekhmenova; O. I. Dunaeva; S. A. Stankevich; V. A. Khazanov
• Keywords: Endothelial Dysfunction

New antithrombotic drug GRS, a soluble guanylate cyclase stimulator, after repeated administration in a dose of 10 mg/kg alleviates the symptoms of endothelial dysfunction in rats with myocardial infarction; it restores antiplatelet activity of the blood vessel wall and vasodilatory function of the endothelium without producing significant effect on endothelium-independent vasodilation. GRS also has direct antiaggregant and antihypertensive effects in therapeutic doses. The obtained data suggest that GRS can be therapeutically useful in patients with cardiovascular diseases accompanied by endothelial dysfunction.